Adial Pharmaceuticals, Inc.

Name: Adial Pharmaceuticals, Inc. standardized financial statements, quarterly
Creator: Listed

ADILNasdaqCIK 1513525HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$52.0m, Q2 FY2026

Net income−$52.0m, Q2 FY2026

Adial Pharmaceuticals, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	period not labelled2024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$m	0.2	0.3	0.5	1.0	1.0	0.7	0.7	0.7	0.5	0.6	0.4	0.4
Operating income	$m	(1.4)	(1.8)	(1.8)	(2.3)	(2.2)	(1.9)	(2.3)	(1.9)	(1.8)	(1.9)	(2.0)	(52.0)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$m	(1.4)	(1.9)	(6.5)	(2.5)	(2.2)	(2.1)	(2.2)	(2.0)	(1.8)	(2.0)	(2.0)	(52.0)
Diluted EPS	$ per share	(1.18)	not reported	(2.19)	(0.59)	(0.38)	not reported	(8.52)	(4.61)	(0.08)	not reported	(1.48)	(11.25)
Basic EPS	$ per share	(1.18)	not reported	(2.19)	(0.59)	(0.38)	not reported	(8.52)	(4.61)	(0.08)	not reported	(1.48)	(11.25)

Balance sheet

Cash and equivalents$5.9m, FY2025

Shareholders' equity−$38.4m, Q2 FY2026

Adial Pharmaceuticals, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	period not labelled2024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	0.3	2.8	not reported	3.3	5.2	3.8	2.4	5.9	4.6	5.9	not reported	not reported
Current assets	$m	1.1	3.2	not reported	3.8	5.6	4.1	2.6	6.1	5.0	6.2	4.8	28.8
Total assets	$m	2.9	4.7	not reported	4.9	6.7	5.0	3.5	6.8	5.7	6.7	5.2	29.1
Current liabilities	$m	0.5	0.7	not reported	0.7	0.8	1.0	1.3	1.2	1.2	1.4	1.5	5.1
Total liabilities	$m	0.5	0.7	not reported	0.7	0.8	1.0	1.3	1.2	1.2	1.4	1.5	28.9
Shareholders' equity	$m	2.3	4.1	6.1	4.3	5.9	4.1	2.1	5.6	4.5	5.3	3.7	(38.4)

Cash flow

Operating cash flow−$6.4m, Q2 FY2026

Share repurchases$0, Q4 FY2023

Adial Pharmaceuticals, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	period not labelled2024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(1,391)	(1,223)	(1,626)	(2,148)	(1,694)	(1,454)	(1,585)	(1,750)	(1,833)	(1,325)	(1,612)	(6,363)
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Share repurchases	$k	not reported	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)4.62m, Q2 FY2026

Adial Pharmaceuticals, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	period not labelled2024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	1.0	26.5	1.1	1.2	3.0	4.2	5.8	0.3	0.4	22.2	1.4	4.6

Shares outstanding: 2.63m at Aug 12, 2026, from the cover of the 10-Q/A filed Oct 21, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. Listed shows no prices and gives no investment advice.